Cargando…
Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023
Chinese health system remains the crucial one for understanding the wider healthcare landscape across the Global South and in particular the leading Emerging Markets. Purpose of our observation was to understand the inner dynamics of mainland Chinese health reforms adopting a lengthy time horizon. W...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469830/ https://www.ncbi.nlm.nih.gov/pubmed/37649062 http://dx.doi.org/10.1186/s12962-023-00461-9 |
_version_ | 1785099533610385408 |
---|---|
author | Jakovljevic, Mihajlo Chang, Hanyu Pan, Jay Guo, Chao Hui, Jin Hu, Hao Grujic, Danko Li, Zhong Shi, Lizheng |
author_facet | Jakovljevic, Mihajlo Chang, Hanyu Pan, Jay Guo, Chao Hui, Jin Hu, Hao Grujic, Danko Li, Zhong Shi, Lizheng |
author_sort | Jakovljevic, Mihajlo |
collection | PubMed |
description | Chinese health system remains the crucial one for understanding the wider healthcare landscape across the Global South and in particular the leading Emerging Markets. Purpose of our observation was to understand the inner dynamics of mainland Chinese health reforms adopting a lengthy time horizon. We have analysed the public reports and seminal evidence on Chinese of multiple waves of national health reforms taking place since 1980s in terms of medical care and pharmaceuticals provision and financing. Chinese international trade with ASEAN nations and wider South-East Asia is accelerating its growth after the recovery of trade routes. In terms of health sector this means that global demand and supply of medical goods, services and pharmaceuticals remains largely driven by Chinese domestic developments. Furthermore, Chinese domestic manufacturing and sales of decent quality medical devices and services have grown exponentially. Some temporary pitfalls and increasing in rural–urban inequalities in equity of access and affordability of medical care and pharmaceuticals did take place. Despite these difficulties to generate a balanced development strategy for the largest global market, this is a clear path upwards. Further upcoming improvements expanding health insurance coverage are in strong demand for certain layers of the society. Domestic bottleneck weaknesses yet remain manufacturing, import and market penetration of cutting-edge pharmaceuticals such as monoclonal antibodies and targeted oncology agents. Yet some of these obstacles are likely to be overcome in foreseeable future with the adoption of responsible strategies by governmental agencies in health care arena. |
format | Online Article Text |
id | pubmed-10469830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104698302023-09-01 Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023 Jakovljevic, Mihajlo Chang, Hanyu Pan, Jay Guo, Chao Hui, Jin Hu, Hao Grujic, Danko Li, Zhong Shi, Lizheng Cost Eff Resour Alloc Review Chinese health system remains the crucial one for understanding the wider healthcare landscape across the Global South and in particular the leading Emerging Markets. Purpose of our observation was to understand the inner dynamics of mainland Chinese health reforms adopting a lengthy time horizon. We have analysed the public reports and seminal evidence on Chinese of multiple waves of national health reforms taking place since 1980s in terms of medical care and pharmaceuticals provision and financing. Chinese international trade with ASEAN nations and wider South-East Asia is accelerating its growth after the recovery of trade routes. In terms of health sector this means that global demand and supply of medical goods, services and pharmaceuticals remains largely driven by Chinese domestic developments. Furthermore, Chinese domestic manufacturing and sales of decent quality medical devices and services have grown exponentially. Some temporary pitfalls and increasing in rural–urban inequalities in equity of access and affordability of medical care and pharmaceuticals did take place. Despite these difficulties to generate a balanced development strategy for the largest global market, this is a clear path upwards. Further upcoming improvements expanding health insurance coverage are in strong demand for certain layers of the society. Domestic bottleneck weaknesses yet remain manufacturing, import and market penetration of cutting-edge pharmaceuticals such as monoclonal antibodies and targeted oncology agents. Yet some of these obstacles are likely to be overcome in foreseeable future with the adoption of responsible strategies by governmental agencies in health care arena. BioMed Central 2023-08-30 /pmc/articles/PMC10469830/ /pubmed/37649062 http://dx.doi.org/10.1186/s12962-023-00461-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Jakovljevic, Mihajlo Chang, Hanyu Pan, Jay Guo, Chao Hui, Jin Hu, Hao Grujic, Danko Li, Zhong Shi, Lizheng Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023 |
title | Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023 |
title_full | Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023 |
title_fullStr | Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023 |
title_full_unstemmed | Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023 |
title_short | Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023 |
title_sort | successes and challenges of china’s health care reform: a four-decade perspective spanning 1985—2023 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469830/ https://www.ncbi.nlm.nih.gov/pubmed/37649062 http://dx.doi.org/10.1186/s12962-023-00461-9 |
work_keys_str_mv | AT jakovljevicmihajlo successesandchallengesofchinashealthcarereformafourdecadeperspectivespanning19852023 AT changhanyu successesandchallengesofchinashealthcarereformafourdecadeperspectivespanning19852023 AT panjay successesandchallengesofchinashealthcarereformafourdecadeperspectivespanning19852023 AT guochao successesandchallengesofchinashealthcarereformafourdecadeperspectivespanning19852023 AT huijin successesandchallengesofchinashealthcarereformafourdecadeperspectivespanning19852023 AT huhao successesandchallengesofchinashealthcarereformafourdecadeperspectivespanning19852023 AT grujicdanko successesandchallengesofchinashealthcarereformafourdecadeperspectivespanning19852023 AT lizhong successesandchallengesofchinashealthcarereformafourdecadeperspectivespanning19852023 AT shilizheng successesandchallengesofchinashealthcarereformafourdecadeperspectivespanning19852023 |